Blog
RSS FeedPosted by Michael Wonder on 17 Jul 2024
CSL Behring announces positive reimbursement decision in Canada for Hemgenix (etranacogene dezaparvovec), the first gene therapy for haemophilia B
16 July 2024 - The positive decision from CADTH recognises the importance of this one-time, single dose innovative treatment for ...
Posted by Michael Wonder on 17 Oct 2022
Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss
17 October 2022 - Quebec leads the way as the first province to reimburse Luxturna (voretigene neparvovec) for previously untreatable inherited ...
Posted by Michael Wonder on 21 Sep 2022
Novartis and the pan-Canadian Pharmaceutical Alliance conclude negotiations for Luxturna, a gene therapy for previously untreatable inherited vision loss
20 September 2022 - Novartis Pharmaceuticals Canada and the pan Canadian Pharmaceutical Alliance have successfully concluded negotiations for Luxturna (voretigene neparvovec), ...
Posted by Michael Wonder on 31 Aug 2022
CADTH ruling on Spinraza (nusinersen) extinguishes hope for adults needing treatment for spinal muscular atrophy
30 August 2022 - CADTH recommends against reimbursement and access to potentially life-altering treatment for adult spinal muscular atrophy patients, discounting ...
Posted by Michael Wonder on 23 May 2022
Draft CADTH recommendation for Spinraza (nusinersen sodium) fails adults in need of treatment for spinal muscular atrophy
20 May 2022 - CADTH does not accept new evidence demonstrating Spinraza's effectiveness and safety for treating spinal muscular atrophy – ...
Posted by Michael Wonder on 18 Oct 2021
Novartis applauds Quebec, the first province to list Zolgensma for the treatment of paediatric patients with spinal muscular atrophy
15 October 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec, effective October 20th will apply for children ...
Posted by Michael Wonder on 14 Oct 2021
Novartis and the pan-Canadian Pharmaceutical Alliance complete negotiations for Zolgensma for the treatment of paediatric patients with spinal muscular atrophy
13 October 2021 - Novartis Pharmaceuticals Canada today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance for a ...
Posted by Michael Wonder on 29 Mar 2021
Alberta family waiting on approval for expensive, life-saving drug for young boy
23 March 2021 - Reign Johnston turned 2 on March 5. One of his grandpas and an uncle came to ...
Posted by Michael Wonder on 28 Jan 2021
Alberta announces funding for pricey gene therapy drug Zolgensma
Alberta Health Minister Tyler Shandro announced funding Wednesday for the gene therapy Zolgensma, which is used to treat toddlers with ...
Posted by Michael Wonder on 21 Dec 2020
Newly approved treatment could save a young child in Edmonton with a rare disease. It costs 2.8 million dollars per dose.
19 December 2020 - Reign Johnston is a happy baby who enjoys painting as much as playing with toys. His green ...
Posted by Michael Wonder on 21 Oct 2020
Canadian baby with spinal muscular atrophy to get ‘world’s most expensive drug’
20 October 2020 - A little over a year ago, the idea of raising US$2.125 million to receive the “world’s ...
Posted by Michael Wonder on 10 Aug 2020
B.C. family nearing finish in race to raise $2.8 million to treat baby's rare disease
8 August 2020 - Parents hope funds will pay for expensive therapy not approved in Canada for type 1 spinal muscular ...
Posted by Michael Wonder on 26 Jul 2020
'I need something to move forward,' says Edmonton mom waiting for approval for son's life saving treatment
24 July 2020 - The family of a little boy in need of a $3 million treatment says they have ...
Posted by Michael Wonder on 18 Jul 2020
'Heartbreaking': Alberta families describe waiting for life-changing drug to be made available in Canada
17 July 2020 - More families are hoping a one-time treatment option for a rare condition will be made available ...
Posted by Michael Wonder on 05 Jul 2020
Clock ticking on Edmonton family's hope for $2.8 million drug treatment for toddler son
3 July 2020 - Family hoping Alberta Health will pay for new drug that must be administered by mid-July. ...